Francis J. Hornicek
University of California, Los Angeles
497 Papers
1.8K Citations
Francis J. Hornicek is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Medicine & Sarcoma. The author has an hindex of 67, co-authored 475 publications. Previous affiliations of Francis J. Hornicek include Harvard University & UCLA Medical Center.
Chat about Author
Papers
RNA sequencing (RNA-Seq) and its application in ovarian cancer.
TL;DR: This review outlines the distinct advantages of RNA-Seq compared to other transcriptomics methods and its recent applications in ovarian cancer.
123
Survival data for patients with malignant schwannoma.
David V Cashen,Robert C Parisien,Kevin A. Raskin,Francis J. Hornicek,Mark C. Gebhardt,Henry J. Mankin +5 more
TL;DR: Overall, the entire series of patients had a survival of 85% at 11 ± 5 years and even more remarkable was the fact that there was no difference between the numbers and outcome statistics for tumors arising spontaneously and those occurring in patients with neurofibromatosis.
120
Clinicopathologic characteristics of poorly differentiated chordoma.
Angela R. Shih,Gregory M. Cote,Ivan Chebib,Edwin Choy,Thomas F. DeLaney,Vikram Deshpande,Francis J. Hornicek,Ruoyu Miao,Joseph H. Schwab,G. Petur Nielsen,Yen-Lin Chen +10 more
TL;DR: Compared to other chordoma subtypes, poorly differentiated chordoma has a significantly decreased mean overall survival after stratification by site, and characteristic SMARCB1 loss and decreased survival compared to conventional/chondroid chordoma.
117
Unicameral Bone Cyst: A Retrospective Study of Three Surgical Treatments
Anthony D. Sung,Megan E. Anderson,Megan E. Anderson,David Zurakowski,Francis J. Hornicek,Mark C. Gebhardt,Mark C. Gebhardt +6 more
TL;DR: SDB is a reasonable first treatment for unicameral bone cysts in the humerus and femur in patients younger than 20 years, being less invasive yet comparable to curettage in preventing recurrence, according to multivariate logistic regression.
Definitive high-dose photon/proton radiotherapy for unresected mobile spine and sacral chordomas.
Yen-Lin Chen,Norbert J. Liebsch,Wendy Kobayashi,Saveli Goldberg,David G. Kirsch,Geoffrey Calkins,Stephanie K. Childs,Joseph H. Schwab,Francis J. Hornicek,Thomas F. DeLaney +9 more
TL;DR: The results support the use of high-dose definitive radiotherapy for patients with medically inoperable or otherwise unresected, mobile spine or sacrococcygeal chordomas.
110